Цитированная литература

1. Барышников А.Ю., Шишкин Ю.В. Иммунологические проблемы апоптоза. – М.: Эдиториал УССР, 2002. – 320с.

2. Льюин Б. Гены: Пер. с англ.- М.:Мир,-1987-544с

3. Фогель Ф., Мотульски А. Генетика человека: в 3-х т. Т.2. Пер. с англ.- М.: Мир-1990-378с

4. Arasteh J.M., Sarvestani E.K., Aflaki E., Amirghofran Z. Fas gene polymorphisms in systemic lupus erythematosus and serum levels of some apoptosis-related molecules. // Int. J. Gynecol. Cancer. 2006. Vol.16. P. 179-182.

5. Arnold P. What are Single Nucleotide Polymorphisms? // Int. J. Cancer. 2008. Vol. 103. P. 221-225.

6. Bel Hadj Jrad B. A polymorphism in FAS gene promoter associated with increased risk of nasopharyngeal carcinoma and correlated with anti-nuclear autoantibodies induction. // Cancer Lett. 2006. Vol. 233. P. 21-27.

7. Ben Aleya W., Sfar I., Mouelhi L. et al. Association of Fas/Apo1 gene promoter (-670 A/G) polymorphism in Tunisian patients with IBD. // World J. Gastroenterol. 2009. Vol. 15, №29. P. 3643-3648.

8. Cao Y., Miao X.P., Huang M.Y. et al. Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. // Mol. Carcinog. 2010. Vol. 49, №11. P. 944-950.

9. Crew K.D. et al. Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. // Carcinogenesis. 2007. Vol. 28. P. 2548-2551.

10. Dybikowska A., Sliwinski W., Emerich J., Podhajska A.J. Evaluation of Fas gene promoter polymorphism in cervical cancer patients. // Int J. Mol. Med. 2004. Vol. 14, №3. P. 475-478.

11. Erdogan M. et al. Fas/Fas ligand gene polymorphism in patients with papillary thyroid cancer in the Turkish population. // J. Endocrinol. Invest. 2007. Vol. 30. P. 411-416.

12. Farre L., Bittencourt A.L., Silva-Santos G. et al. Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. // Virus Res. 2012. Vol. 163, №1. P. 178-182.

13. Gormus U. et al. Fas-1377 A/G polymorphism in lung cancer. // In Vivo. 2007. Vol. 21. P. 663-666.

14. Gormus U. et al. Fas-1377A/G and FasL-844 T/C gene polymorphisms and epithelial ovarian cancer. // Anticancer Res. 2007. Vol. 27. P. 991-994.

15. Hsu P.I. et al. Polymorphisms of death pathway genes FAS and FASL and risk of premalignant gastric lesions. // Anticancer Res. 2008. Vol. 28. P. 97-103.

16. Huang Q.R., Morris D., Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. // Mol. Immunol. 1997. Vol. 34. P. 577–582.

17. Ikehara S.K. et al. A polymorphism of C-to-T substitution at -31 IL1B is associated with the risk of advanced gastric adenocarcinoma in a Japanese population. // J. Hum. Genet. 2006. Vol. 51. P. 927-933.

18. Kanemitsu S., Ihara K., Saifddin A. et al. A functional polymorphism in Fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. // J. Rheumatol. 2002. Vol. 29. P. 1183–1188.

19. Koshkina N.V. et al. Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients. // J. Pediatr. Hematol. Oncol. 2007. Vol. 29. P. 815-821.

20. Krippl P., Langsenlehner U., Renner W. et al. Polymorphisms of Death Pathway Genes FAS and FASL in Esophageal Squamous-Cell Carcinoma. // J. Nat. Cancer Inst. 2004. Vol. 96, №19. Р. 1478-1479.

21. Lai H.C. et al. Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: an analysis of haplotype and gene-gene interaction. // Gynecol. Oncol. 2005. Vol. 99. P. 113-118.

22. Lai H.C. et al. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. // Int. J. Cancer. 2003. Vol. 103. P. 221-225.

23. Lei D., Sturgis E. M., Wang L.-E. et al. FAS and FASLG Genetic Variants and Risk for Second Primary Malignancy in Patients with Squamous Cell Carcinoma of the Head and Neck. // Cancer Epidemiol. Biomarkers Prev. 2010. Vol. 19. P. 1484-1491.

24. Li C. et al. Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis. // Pharmacogenet. Genomics. 2006. Vol. 16. P. 245-251.

25. Li C. et al. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. // Pharmacogenet. Genomics. 2006. Vol. 16 P. 253-263.

26. Lima L. et al. Association between FAS polymorphism and prostate cancer development. // Prostate Cancer Prostatic Dis. 2008. Vol. 11. P. 94-98.

27. Lima L., Calais da Silva F. M., Calais da Silva F. E. et al. Fas-670 polymorphism and prostate cancer. // J. Clin. Onc. 2007. Vol.25, №18. Р. 21028.

28. Marín L.A., Muro M., Moya-Quiles M.R. et al. Study of Fas (CD95) and FasL (CD178) polymorphisms in liver transplant recipients. // Tissue Antigens. 2006. Vol. 67, №2. P. 117-126.

29. Melville B. What are ОНП? // Eur. J. Hum. Genet. 2000. Vol. 8, №2. Р. 154-165.

30. Nelson H.H. et al. Fas/APO-1 promoter polymorphism is not associated with non-melanoma skin cancer. // Cancer Epidemiol. Biomarkers Prev. 2001. Vol. 10. P. 809-810.

31. Norrgard K., Schultz J. et al. Natural selection has driven population differentiation in modern humans. // Nature Genetics. 2008. Vol. 40. P. 340-345.

32. Park S.H. et al. Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population. // Lung Cancer. 2006. Vol. 54. P. 303-308.

33. Pengfei S., Qi D., Chao Q. et al. Functional polymorphisms in cell death pathway genes FAS and FAS ligand and risk of prostate cancer in a Chinese population. // The Prostate. 2011.Vol. 71, №10. P. 1122–1130.

34. Sibley K. et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. // Cancer Res. 2003. Vol. 63. P. 4327-4330.

35. Smith K., Lancia G., Lippert R., Schwartz R. ОНП Problems, Complexity and Algorithms. // LNCS. 2002. Vol. 2161. P. 182-193.

36. Sun T. et al. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. // J. Exp. Med. 2005. Vol. 202. P. 967-974.

37. Sun T. et al. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. // J. Natl. Cancer Inst. 2004. Vol. 96. P. 1030-1036.

38. Sziller I., Nguyen D., Halmos A. et al. An A>G polymorphism at position −670 in the Fas (TNFRSF6) gene in pregnant women with pre-eclampsia and intrauterine growth restriction . // Mol. Hum. Reprod. 2005. Vol.11, №3. Р. 207-210.

39. Tamandani D.M. et al. Association of Fas-670 gene polymorphism with risk of cervical cancer in North Indian population. // Clin. Exp. Obstet. Gynecol. 2008. Vol. 35. P. 183-186.

40. Ter-Minassian M. et al. Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. // Carcinogenesis. 2008. Vol. 29. P. 2147-2152.

41. Ueda M. et al. Fas gene promoter -670 polymorphism (A/G) is associated with cervical carcinogenesis. // Gynecol. Oncol. 2005. Vol. 98. P. 129-133.

42. Ueda M. et al. Fas gene promoter -670 polymorphism in gynecological cancer. // Int. J. Gynecol. Cancer. 2006. Vol. 16. P. 179-182.

43. Vallinoto A.C., Santana B.B., Dos Santos E.L. et al. FAS -670A/G single nucleotide polymorphism may be associated with human T lymphotropic virus-1 infection and clinical evolution to TSP/HAM. // Eur. J. Gynaecol. Oncol. 2009. Vol. 30, №2. P. 142-144.

44. Wang L.E. et al. Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. // Lung Cancer. 2003. Vol. 42. P. 1-8.

45. Yang M. et al. Functional variants in cell death pathway genes and risk of pancreatic cancer. // Clin. Cancer Res. 2008. Vol. 14. P. 3230-3236.

46. Zhang B., Sun T., Xue L. et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. // Carcinogenesis. 2007. Vol. 28, №5. P. 1067-1073.

47. Zhang H. et al. Importance of FAS-1377, FAS-670, and FASL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: a case-control analysis. // Cancer J. 2007. Vol. 13. P. 233-237.

48. Zhang X., Miao X., Sun T. et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. // J. of Med. Genet. 2005. Vol. 42, №6. P. 479-484.

49. Zhang Z. et al. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. // Clin. Cancer Res. 2006. Vol. 12. P. 5596-5602.

50. Zhang Z., Xue H., Gong W. et al. FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies.// Carcin. 2009. Vol. 30, №3. Р.487-493.

51. Zhou R.M., Wang N., Chen Z.F. et al. Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma. // J. Gastroenterol. Hepatol. 2010. Vol. 25, №3. P. 555-561.

52. Zhu Q., Wang T., Ren J. et al. FAS-670A/G polymorphism: A biomarker for the metastasis of nasopharyngeal carcinoma in a Chinese population. Clin. Chim. Acta. 2010. Vol. 411, №3, 4. P.179-183.

53. Zoodsma M. et al. Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease. // Int. J. Gynecol. Cancer 2005. Vol. 15. P. 282-290.

54. Zucchi F., da Silva I.D., Ribalta J.C. et al. Fas/CD95 promoter polymorphism gene and its relationship with cervical carcinoma. // Immunol. Invest. 2010. Vol. 39, №1. P. 27-38.